N. Barnes (London, United Kingdom), G. Canonica (Genoa, Italy)
Sublinguial allergen extract immunotherapy in a rush pattern to reach the maintainance faster
N. Pandey, S. Kole, S. P. Singh, S. Gupta Bhattacharya, S. Kumar, S. Bibhore (Kolkata, Purnia, Kol, Panchkulla, India)
|   |
Adherence to sublingual immunotherapy in patients allergic to mites
B. Omarjee, B. Tanguy, Z. Rida (Saint Denis, Reunion)
| |
Maintenance schedule of subcutaneous allergoid immunotherapy more efficacious than pre-seasonal
E. Swiebocka, G. Siergiejko, P. Rapiejko, Z. Siergiejko (Bialystok, Warsaw, Poland)
| |
Pollen asthma treatment: Comparative efficacy study
I. Sygaieva (Kyiv, Ukraine)
| |
Omalizumab in asthmatics with IgE levels > 700 IU/ml
D. Maselli, J. Diaz, J. Peters (San Antonio, United States Of America)
| |
Effects of add-on omalizumab therapy on airway wall thickening in severe persistent asthma
M. Hoshino (Atami, Japan)
| |
Decreasing dose protocol for omalizumab treatment in oral corticosteroid allergic asthma patients
C. Domingo, X. Pomares, J. Casabon, A. García, C. Veigas, C. Montón (Sabadell, Spain)
| |
The APEX study: Retrospective review of oral corticosteroid use in omalizumab-treated severe allergic asthma patients in UK clinical practice
N. Barnes, on Behalf of the APEX Study Investigators, A. Radwan (London, Frimley/Camberley, United Kingdom)
| |
OPURIT: Omalizumab-protected ultra rush specific immunotherapy in severe asthmatic patients with house dust mite allergy
T. Harr, P. Schmid-Grendelmeier (Zurich, Switzerland)
| |
Biological monitoring of cellular effects of omalizumab with basophil degranulation test (BAT) in severe asthma
A. Stanziola, F. Perna, D. Radicella, C. Vitale, E. Carpentieri, C. Russo, M. Sofia (Naples, Italy)
| |
The APEX study: A retrospective review of responses of severe allergic asthma patients to omalizumab on continuous or non-continuous oral corticosteroids in UK clinical practice
R. Niven, on Behalf of the APEX Study Investigators, A. Radwan (Manchester, Frimley/Camberley, United Kingdom)
| |
Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: Pooled data from 3 UK centres
M. Britton, T. Howes, A. Boland, D. Saralaya, D. Hepburn, M. Nordstrom, K. Welham, K. Regan, I. Kasujee (Chertsey, Colchester, Bradford, Frimley/Camberley, United Kingdom)
| |
ROMA (registry omalizumab in Malaga): Study of 84 patients
M. Martin-Rebollo, A. Padilla Galo, M. P. Alfonso, L. N. Alberto (Malaga, Marbella, Spain)
| |
Long-term treatment with monoclonal antibodies anti-IgE in severe asthma: Follow-up of ten patients
M. Brunori, R. Pierro, F. S. Pignataro, G. Onelli (Rome, Italy)
| |
Omalizumab and voriconazole in allergic broncopulmonary aspergillosis (A case series)
A. Stanziola, E. Carpentieri, C. Vitale, M. Pitassi, N. Sorrentino, M. Sofia (Naples, Italy)
| |
Eligibility for treatment with omalizumab in Italy and Germany
R. Buhl, G. W. Canonica, A. Gili Marco, C. Ruland (Mainz, Germany; Genoa, Italy; Basel, Switzerland)
| |
Cytokine production profile of T-lymphocytes and frequence of regulatory T-cells in patients with allergic asthma receiving anti-IgE therapy
I. Haasler, J. Weber, I. Bellinghausen, S. Korn, J. Saloga, R. Buhl, C. Taube (Mainz, Germany)
| |